Clinical Trial Update: ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing ACVBP alone versus ACVBP plus Rituximab in low-risk localized diffuse large B-cell lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• ACVBP
• Rituxan (rituximab)

Snippet

Sponsor: Lymphoma Study Association | Conditions: Diffuse Large Cell Lymphoma | Phase 3 | Status: TERMINATED